{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:10:16Z","timestamp":1790982616699,"version":"4.1.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Observational data indicate that newer vitamin D compounds such as paricalcitol can suppress serum intact parathyroid hormone (iPTH) and reduce proteinuria in patients with CKD. To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis of the published randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>MEDLINE, Embase, the Cochrane Library, and article reference lists were searched for RCTs that compared paricalcitol with placebo in the treatment of patients with stage 2\u20135 CKD. The quality of the studies was evaluated using the Jadad method. The results are summarized as risk ratios (RRs) for dichotomous outcomes or mean differences for continuous outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine studies (832 patients) were included. Compared with placebo, paricalcitol suppressed serum iPTH (RR, 6.37; 95% confidence interval [95% CI], 4.64\u20138.74;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) and reduced proteinuria (RR, 1.68; 95% CI, 1.25\u20132.25;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Compared with the control group, the RR for hypercalcemia associated with paricalcitol use was 2.25 (95% CI, 0.81\u20136.26;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.12). Patients receiving paricalcitol therapy did not have an increased risk of endocrine system and cardiovascular system adverse effects (RR, 1.07; 95% CI, 0.84\u20131.36;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.58).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We con\ufb01rm that paricalcitol suppresses iPTH and lowers proteinuria in patients with stage 2\u20135 CKD without an increased risk of adverse events. A trend toward increased hypercalcemia did not reach statistical signi\ufb01cance, but may be clinically relevant. A randomized trial is needed to determine if paricalcitol affects the development of ESRD or mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.03000311","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T05:52:50Z","timestamp":1325829170000},"page":"391-400","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy and Safety of Paricalcitol Therapy for Chronic Kidney Disease"],"prefix":"10.2215","volume":"7","author":[{"given":"Jun","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20230811","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease.","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"R2-6-20230811","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","article-title":"The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure.","volume":"29","author":"Martinez","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R3-6-20230811","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R4-6-20230811","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS).","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R6-6-20230811","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"R7-6-20230811","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R8-6-20230811","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-6-20230811","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"R16-6-20230811","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease.","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R17-6-20230811","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0197-2456(86)90034-6","article-title":"Analysis of data from multiclinic trials.","volume":"7","author":"Fleiss","year":"1986","journal-title":"Control Clin Trials"},{"key":"R18-6-20230811","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: An update.","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"R19-6-20230811","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R24-6-20230811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000109398","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.","volume":"28","author":"Ross","year":"2008","journal-title":"Am J Nephrol"},{"key":"R26-6-20230811","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","article-title":"Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial.","volume":"54","author":"Fishbane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R28-6-20230811","first-page":"CD008175","article-title":"Vitamin D compounds for people with chronic kidney disease not requiring dialysis.","volume":"7","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R30-6-20230811","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: Vitamin D compounds in chronic kidney disease.","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"R35-6-20230811","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201203000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:45Z","timestamp":1786369305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201203000-00006"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.03000311","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}